SLC5A2 and type 2 diabetes mellitus: Around the time that currently available SGLT2 inhibitors were progressing through clinical trials, the United States Food and Drug Administration (FDA) issued an additional requirement for phase III clinical trials of antidiabetic medications for T2DM (40).